UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2020

BridgeBio Pharma, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-38959**	**84-1850815**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

421 Kipling Street **Palo Alto, CA**	**94301**
(Address of principal executive offices)	**(Zip Code)**

(650) 391-9740
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	**BBIO**	**The Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 29, 2020, BridgeBio Pharma, Inc. will present at its Research and Development Day. The slide presentation to be presented at the Research and Development Day is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.

The information responsive to Item 7.01 of the Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Presentation of BridgeBio Pharma, Inc., dated September 29, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BridgeBio Pharma, Inc.

Date: September 29, 2020

/s/ Brian C. Stephenson
Brian C. Stephenson
Chief Financial Officer

Exhibit 99.1

bridgebio

hope through
rigorous science

R&D Day

September 29, 2020

Forward-Looking Statements and Disclaimer

Statements in this Presentation that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding BridgeBio Pharma, Inc.'s (the "Company's") research and clinical development plans, expected manufacturing capabilities, strategy, regulatory matters, market size and opportunity, future financial position, future revenue, projected costs, prospects, plans, objectives of management, and the Company's ability to complete certain milestones. Words such as "believe," "anticipate," "plan," "expect," "intend," "will," "may," "goal," "potential," "should," "could," "aim," "estimate," "predict," "continue" and similar expressions or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are neither forecasts, promises nor guarantees, and are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks inherent in developing therapeutic products, the success, cost, and timing of the Company's product candidate development activities and ongoing and planned preclinical studies and clinical trials, , trends in the industry, the legal and regulatory framework for the industry, the Company's ability to obtain and maintain regulatory approval for its product candidates, the Company's ability to commercialize its product candidates, future agreements with third parties in connection with the development or commercialization of the Company's product candidates, the size and growth potential of the market for the Company's product candidates, the accuracy of the Company's estimates regarding expenses, future revenue, future expenditures and needs for and ability to obtain additional financing, the Company's ability to obtain and maintain intellectual property protection for its product candidates, potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, and those risks and uncertainties described under the heading "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") and in subsequent filings made by the Company with the SEC, which are available on the SEC's website at www.sec.gov. In light of these risks and uncertainties, many of which are beyond the Company's control, the events or circumstances referred to in the forward-looking statements, expressly or implicitly, may not occur. The actual results may vary from the anticipated results and the variations may be material. You are cautioned not to place undue reliance on these forward-looking statements, which speak the Company's current beliefs and expectations only as of the date this Presentation is given. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this Presentation in the event of new information, future developments or otherwise. No representation is made as to the safety or effectiveness of these product candidates for the therapeutic use for which such product candidates are being studied.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this Presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

The Company is the owner of various trademarks, trade names and service marks. Certain other trademarks, trade names and service marks appearing in this Presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this Presentation are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

BridgeBio Pharma: Hope through rigorous science

Our mission: To **discover, create**, **test** and **deliver** transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers

BridgeBio corporate overview



We are at Day 1 in the era of genetic medicine



Source: Claussnitzer *et al.*, *Nature* 2020

A vast opportunity to help patients

~27 million Americans are living with a genetic diseases

50% Of people affected are children

Only 5% Of these diseases have an approved therapy

US prevalence, mn



Source: Global Genes, American Cancer Society, American Heart Association, Alzheimer's Association, Arthritis Foundation, Bailey *et al., Cell* 2018

Our strategy is simple



History teaches us about strategy:		BBIO applications:
1. Right playing field		1. Genetic disease
2. Right tenets		2. Beautiful science, NPV positive
3. Stay adaptive		3. No initial focus on TA, disease, or modality. Repeated application

Our organizational principles enable scale



History teaches us about growth:		BBIO applications:
1. Simple rules repeated at many levels	→	1. Simple rules – put patients first, think independently and let science speak, be efficient
2. De-centralized cities grow with *returns to scale*, centralized companies slow with economies of scale	→	2. De-centralized approach – small teams that focus and are incented at the level of each asset, scale that allows for rapid failure, learning

Result: Pipeline momentum



2015

- BridgeBio founded
- 1 pipeline program

2017

- 10 pipeline programs
- 3 clinical compounds

2020

- 20+ programs
- Multiple $1B+ opportunities in Ph3
- Two NDA submissions
- >10 INDs in 5 years

Increasing returns to scale – BridgeBio since IPO

Achievement:

- NDA for MoCD Type A accepted, ODD & Fast Track received for 2L CCA program
- 7 INDs filed
- Six new clinical trials initiated (16 total), >350 trial sites across 25 countries
- 8 new programs, including LGMD2i and ADH1, both in the clinic
- TTR clinical data, DEB clinical data, CAH and Canavan pre-clinical data, achon pre-clinical data, TIO data



BridgeBio corporate overview



BridgeBio drug engineering basics: our platform

Discover	Create	Test	Deliver
Novel genetic disease targets	**Medicines with industry-leading research capabilities**	**Our drugs through global development footprint**	**Our products to patients through commercial infrastructure**
			
Well described diseases than can be targeted at their source	Tailored therapeutic technologies to create first or best-in-class medicines	Broad clinical development capabilities across therapeutic areas and geographies	Building the capabilities to deliver genetic medicines to patients globally

Capabilities to identify new genetic disease targets at scale

Discover

Our target identification engine is driven by three core areas of strength:

Computational genomics / statistical genetics

- Mining of large genotype-phenotype databases
- *De novo* target discovery
- Target validation
- Indication expansion

Systematic disease mapping

- Manual annotation and prioritization of the 7K known genetic diseases

Partnering with top academic researchers

- 15 current partnerships

Johns Hopkins University

The University of Texas MD Anderson Cancer Center — Making Cancer History®

Boston Children's Hospital — Until every child is well

Cincinnati Children's

Stanford University

Discover

Scientific insight and judgment from industry leaders with a proven track record

Charles Homcy, MD
Founder and Chairman of Pharmaceuticals

MyoKardia

GBT

Frank McCormick, PhD
Founder and Chairman of Oncology

ONYX PHARMACEUTICALS

UCSF

Richard Scheller, PhD
Chairman of R&D

Genentech

23andMe

Len Post, PhD
Advisor

BIOMARIN

LEAD THERAPEUTICS

Phil Reilly, MD, JD
Advisor

THIRD ROCK VENTURES

bluebirdbio

Create

We select the optimal therapeutic modality to target each disease at its source

Industry-leading capabilities across 4 modalities:

Medicinal chemistry

- Molecular dynamics
- Reversible and irreversible chemistry
- Topical formulations

Optimal use: Inhibition of GOF or allosteric activation of LOF mutations



Gene therapy

- Vector optimization
- Novel capsid engineering
- Analytical assay development

Optimal use: Replacement of intracellular protein in LOF diseases

Therapeutic proteins

- Large protein manufacturing
- Formulation expertise
- Comparability assay development

Optimal use: Replacement of extracellular protein in LOF diseases



Antisense oligonucleotides

- Target mapping with functional genomics
- Activity screening assay development
- Novel backbone and base chemistry

Optimal use: Inhibition of GOF or activation of WT allele in LOF diseases



GOF = gain-of-function, LOF = loss-of-function, WT = wild type

Create

Research leaders with a productive history developing novel therapeutics

Mendelian	Oncology	Gene therapy

Uma Sinha, PhD
Chief Scientific Officer

GBT
PORTOLA PHARMACEUTICALS

Robert Zamboni, PhD
Chemistry

MERCK FROSST

Eli Wallace, PhD
Chief Scientific Officer, Oncology

Peloton Therapeutics
ARRAY BIOPHARMA

Pedro Beltran, PhD
SVP, Biology

AMGEN
UNITY BIOTECHNOLOGY

Clayton Beard, PhD
SVP, Research and Development

PRECISION BIOSCIENCES
NOVARTIS

Our global clinical development footprint

Test

- **16 ongoing trials** across 5 different therapeutic areas, >350 trial sites, and 25 countries
- **Creative clinical and regulatory strategy,** e.g., unique, nested Phase 3 trial design for acoramadis in ATTR
- **Central operations toolkit** for enrollment, protocol quality, site activation, CRO quality, regional performance
- **Expert, dedicated R&D teams** in each therapeutic area
  - Cardio/renal: Jonathan Fox, MD, PhD MyoKardia AstraZeneca
  - Oncology: Susan Moran, MD genzyme
  - Gene Therapy: Adam Shaywitz, MD, PhD BIOMARIN AMGEN

Countries with BridgeBio trial sites



Deliver

Building capabilities to deliver our products to patients across the globe

- **Global commercial infrastructure** to leverage our drug and disease expertise
- **Diagnostic partnerships** to identify patients in need of our medicines
- **Disease awareness strategies** including close partnerships with patient advocacy groups
- **Country-specific Early Access Programs** (EAP) and patient assistance programs
- **Commercial partners in strategic geographies:**

FGFRi and SHP2i in China: LianBio

TTR in Japan: Alexion

MoCD type A in Israel: Medison Delivering Innovative Healthcare

Key people: Matt Outten (CCO), Jennifer Cook (BOD), Brent Saunders (BOD)

The platform is delivering

Discover
Novel genetic disease targets

20+
Disclosed programs in the pipeline

Create
Medicines with industry-leading research capabilities

>10
INDs since 2015

Test
Our drugs through global development footprint

16
Clinical trials across the globe

Deliver
Our products to patients through commercial infrastructure

2
Product launches expected in 2021

BridgeBio corporate overview



Our pipeline of 20+ development programs spans multiple therapeutic areas and drug modalities

Small molecule | Topical small molecule | Biologics | Gene therapy

Portfolio segment	Program	Drug mechanism	Diseases	Patient pop. (US+EU)	Modality	Preclinical: Discovery	Preclinical: IND-enabling	Clinical: Phase1	Clinical: Phase 2	Clinical: Phase 3
Mendelian	Acoramidis	TTR stabilizer	ATTR-CM	>400K	Small molecule					
	Fosdenopterin	cPMP replacement	MoCD type A	100	Small molecule					NDA filed
	Infigratinib	Low-dose FGFR1-3i	Achondroplasia	55K	Small molecule					
	Encaleret	CaSR antagonist	ADH1 / HP	12K[1] / 200K	Small molecule					
	Zuretinol	Synthetic retinoid	IRD (RPE65 or LRAT)	3K	Small molecule					
	BBP-418	Glycosylation substrate	LGMD2i	7K	Small molecule					
	BBP-711	GO1 inhibitor	PH1 / FSF	5K / 1.5M	Small molecule					
	BBP-671	PanK activator	PKAN / OA	7K	Small molecule					
	BBP-761	Succinate prodrug	LHON	20K	Small molecule					
	BBP-472	PI3Kβi	PTEN autism	120K	Small molecule					
Genetic Dermatology	Patidegib[2]	Topical SMOi	Gorlin / BCC	120K	Topical small molecule					
	BBP-589	Recombinant COL7	RDEB	1.5K	Biologics					
	BBP-681	Topical PI3Kai	VM / LM	117K	Topical small molecule					
	BBP-561	Topical KLK 5/7i	Netherton	11K	Topical small molecule					
Targeted Oncology	Infigratinib	FGFR1-3i	FGFR+ tumors	37K	Small molecule					
	BBP-398	SHP2i	Multiple tumors	>500K	Small molecule					
	BBP-454	Pan-mutant KRASi	KRAS+ tumors	>500K	Small molecule					
	BBP-954	GPX4i	Multiple tumors	>500K	Small molecule					
Gene Therapy	BBP-631	21-OH gene therapy	CAH	>75K	Gene therapy					
	BBP-812	ASPA gene therapy	Canavan	1K	Gene therapy					
	BBP-815	TMC1 gene therapy	Genetic hearing loss	10K	Gene therapy					

1 US carriers; 2 We are party to an option agreement pursuant to which LEO Pharma A/S has been granted an exclusive, irrevocable option to acquire PellePharm, including the BBP-009 program. If the option is exercised by LEO Pharma A/S, we will no longer have rights to develop and commercialize BBP-009.

Four core value drivers over the next 12-24 months

Program	Opportunity size	Status	Upcoming event(s)
Acoramidis: TTR stabilizer for ATTR		ATTR-CM Ph3 ongoing	❑ Topline Ph3 part A data late-2021 / early-2022 ❑ Topline Ph3 part B data 2023
Low-dose infigratinib (FGFRi) for achondroplasia		Enrolling Ph2 study	✓ Dose first child ❑ Phase 2 data 2021
Gene therapy for congenital adrenal hyperplasia (BBP-631)		GLP tox ongoing	❑ File IND ❑ Phase 1/2 data 2021
Encaleret: CaSR inhibitor for autosomal dominant hypocalcemia type 1 (ADH1)		Ph2 ongoing	✓ FPI in Ph2 study ❑ Phase 2 data 2021

A pipeline with multi-blockbuster potential

$1B+
opportunities
in the pipeline

1) **Acoramidis** for ATTR CM and PN
2) **Low-dose infigratinib** for achondroplasia
3) **AAV5 gene therapy** for congenital adrenal hyperplasia
4) **High-dose infigratinib** for adjuvant urothelial carcinoma
5) **Pan-mutant KRAS inhibitor** for KRAS+ cancer
6) **SHP2 inhibitor** for RAS and kinase mutant cancer
7) **GPX4 inhibitor** for multiple tumor types
8) **GO1 inhibitor** for frequent kidney stone formers

Thank you to our speakers

Speaker	Related program
 **Ravi Saravirayan, MD, PhD** Professor and Group Leader, Murdoch Children's Research Institute Head of Clinical Genetics Services at the Victorian Clinical Genetic Services	Low-dose infigratinib (FGFRi) for achondroplasia
 **Julian Gillmore, MD, PhD** Head, Centre for Amyloidosis & Acute Phase Proteins, University College London	Acoramidis: TTR stabilizer for ATTR cardiomyopathy
 **Kyriakie (Kiki) Sarafoglou, MD** Associate Professor, University of Minnesota Medical School and College of Pharmacy	Gene therapy for congenital adrenal hyperplasia (BBP-631)
 **Michael Collins, MD** Chief of the Skeletal Disorders and Mineral Homeostasis Section, National Institutes of Health	Encaleret: CaSR inhibitor for autosomal dominant hypocalcemia type 1 (ADH1)
 **Frank McCormick, PhD** BridgeBio Chairman of Oncology Professor, Helen Diller Family Comprehensive Cancer Center University of California San Francisco	Oncology research, KRAS